-+ 0.00%
-+ 0.00%
-+ 0.00%

CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody conjugate drug TQB2102.

Zhitongcaijing·08/31/2026 10:17:07
Listen to the news
CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody conjugate drug TQB2102.